$CNBX
CNBX Pharmaceuticals Inc.

2025 Q1 Form 10-Q Financial Statement

#000168316825000267 Filed on January 13, 2025

View on sec.gov

Income Statement

Concept 2025 Q1 2024 Q4
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $0.00
YoY Change -100.0%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $36.84K
YoY Change -85.9%
Operating Profit -$36.84K
YoY Change -78.57%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.485K
YoY Change -137.52%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$34.35K
YoY Change -80.76%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 31.11M shares 31.11M shares
Diluted Shares Outstanding 31.11M shares

Balance Sheet

Concept 2025 Q1 2024 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $17.34K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $22.31K
YoY Change -85.22%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $22.31K
Total Long-Term Assets $0.00
Total Assets $22.31K
YoY Change -94.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.537M
YoY Change 2.19%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.537M
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$24.99M
YoY Change 2.25%
Common Stock $3.111K
YoY Change 9.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.514M
YoY Change
Total Liabilities & Shareholders Equity $22.31K
YoY Change -94.24%

Cashflow Statement

Concept 2025 Q1 2024 Q4
OPERATING ACTIVITIES
Net Income -$34.35K
YoY Change -80.76%
Depreciation, Depletion And Amortization $0.00
YoY Change -100.0%
Cash From Operating Activities -$39.08K
YoY Change -45.61%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $30.00K
YoY Change 20.03%
NET CHANGE
Cash From Operating Activities -$39.08K
Cash From Investing Activities $0.00
Cash From Financing Activities $30.00K
Net Change In Cash -$9.077K
YoY Change -81.11%
FREE CASH FLOW
Cash From Operating Activities -$39.08K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22471309 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24988752 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24954400 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
-2514332 usd
CY2024Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--08-31
CY2024Q4 us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2024Q4 dei Document Type
DocumentType
10-Q
CY2024Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q4 dei Document Period End Date
DocumentPeriodEndDate
2024-11-30
CY2024Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q4 dei Entity Registrant Name
EntityRegistrantName
CNBX PHARMACEUTICALS INC.
CY2024Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Bethesda
CY2024Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20814
CY2024Q4 dei City Area Code
CityAreaCode
(877)
CY2024Q4 dei Local Phone Number
LocalPhoneNumber
424-2429
CY2024Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q4 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q4 dei Entity Shell Company
EntityShellCompany
false
CY2025Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31111352 shares
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17339 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26416 usd
CY2024Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4969 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4969 usd
CY2024Q4 us-gaap Assets Current
AssetsCurrent
22308 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
31385 usd
CY2024Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2024Q4 us-gaap Assets
Assets
22308 usd
CY2024Q3 us-gaap Assets
Assets
31385 usd
CY2024Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
51992 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
217774 usd
CY2024Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1328232 usd
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1295107 usd
CY2024Q4 CNBX Due To Related Party Current
DueToRelatedPartyCurrent
1156416 usd
CY2024Q3 CNBX Due To Related Party Current
DueToRelatedPartyCurrent
998484 usd
CY2024Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2536640 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2511365 usd
CY2024Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-2479980 usd
CY2024Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22308 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2024Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31111352 shares
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31111352 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31111352 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31111352 shares
CY2024Q4 us-gaap Common Stock Value
CommonStockValue
3111 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
3111 usd
CY2024Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22471309 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31385 usd
CY2023Q4 us-gaap Revenues
Revenues
89437 usd
CY2024Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
CY2024Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36837 usd
CY2024Q4 us-gaap Operating Expenses
OperatingExpenses
36837 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
261337 usd
CY2024Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-36837 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
148919 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-171900 usd
CY2024Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2485 usd
CY2023Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6623 usd
CY2023Q4 us-gaap Depreciation
Depreciation
39461 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-34352 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-178523 usd
CY2024Q4 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
CY2023Q4 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
CY2024Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34352 usd
CY2023Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-178523 usd
CY2024Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.001
CY2024Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.001
CY2024Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
3122 usd
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.006
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.006
CY2024Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31111352 shares
CY2024Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31111352 shares
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27760802 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27760802 shares
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-2479980 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-34352 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
-2514332 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2017289 usd
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34975 usd
CY2023Q4 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
65908 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-178523 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2094929 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-34352 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-178523 usd
CY2024Q4 us-gaap Depreciation
Depreciation
0 usd
CY2023Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
11451 usd
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
34975 usd
CY2024Q4 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-0 usd
CY2023Q4 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-25323 usd
CY2024Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-7847 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4533 usd
CY2024Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39077 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-71846 usd
CY2024Q4 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
-0 usd
CY2023Q4 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
1196 usd
CY2024Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1196 usd
CY2024Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
30000 usd
CY2023Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
24993 usd
CY2024Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30000 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24993 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9077 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-48049 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26416 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
129696 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17339 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81647 usd
CY2024Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
112418 usd
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-34352 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24988752 usd
CY2024Q4 dei Amendment Flag
AmendmentFlag
false
CY2024Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001343009
CY2024Q4 us-gaap Revenues
Revenues
0 usd
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
112418 usd
CY2024Q4 dei Entity File Number
EntityFileNumber
000-52403
CY2024Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5644005
CY2024Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
#3 Bethesda Metro Center
CY2024Q4 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 700
CY2024Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD

Files In Submission

Name View Source Status
0001683168-25-000267-index-headers.html Edgar Link pending
0001683168-25-000267-index.html Edgar Link pending
0001683168-25-000267.txt Edgar Link pending
0001683168-25-000267-xbrl.zip Edgar Link pending
cnbx-20241130.xsd Edgar Link pending
cnbx_ex3101.htm Edgar Link pending
cnbx_ex3102.htm Edgar Link pending
cnbx_ex3201.htm Edgar Link pending
cnbx_ex3202.htm Edgar Link pending
cnbx_i10q-113024.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cnbx-20241130_cal.xml Edgar Link unprocessable
cnbx-20241130_def.xml Edgar Link unprocessable
cnbx-20241130_lab.xml Edgar Link unprocessable
cnbx-20241130_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cnbx_i10q-113024_htm.xml Edgar Link completed